Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis

Mediators of Inflammation

Volumn 7, Issue 5, 1998, Pages 347-353

  Robak, T ^a   Gladalska, A ^b   Stepien H ^a   Robak, E ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b 1st Department of Hematology City Hospital   (Poland)

Author keywords

Cilary neurotrophic factor; Disease activity; Interleukin 6; Leukaemia inhibitory factor; Rheumatoid arthritis; Soluble interleukin 6 receptor

Indexed keywords

CILIARY NEUROTROPHIC FACTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEUKEMIA INHIBITORY FACTOR;

ADULT; AGED; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

MYRISTICA FRAGRANS;

EID: 0031744306     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/09629359890875     Document Type: Article

References (46)

1. Weyand CM, Goronzy JJ. Pathogenesis of rheumatoid arthritis. Med Clin N Amer 1997; 81: 29-55.
2. Klareskog L, Ronnelid J, Holm G. Immunopathogenesis and immunotherapy in rheumatoid arthritis: an area in transition. J Intern Med 1995; 238: 191-206.
3. Koch AE, Kunkel SL, Striater RM. Cytokines in rheumatoid arthritis. J Invest Med 1995; 43: 28-38.
4. Robak T, Gladalska A, Stepień M. Tumour necrosis factor (TNF) family of receptors ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 1998; 9: 145-154.
5. Holt I, Cooper RG, Denton J, Meager A, Hopkins SJ. Cytokine interrelationships and their association with disease activity in arthritis. Br J Rheumatol 1992; 31: 725-733.
6. Brennan FM, Maini N, Feldmann M. Cytokine expression in chronic inflammatory disease. Br Med Bull 1995; 51: 368-384.
7. Ronnelid J, Berg L, Rogberg S, Nilsson A, Albertsson K, Klareskog L. Production of T-cell cytokines at the single-cell level in patients with inflammatory arthritides: enhanced activity in synovial fluid compared to blood. Br J Rheumatol 1998; 37: 7-14.
8. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993; 54: 1-78.
9. Bauer J, Herrmann F. Interleukin-6 in clinical medicine. Ann Hematol 1991; 62: 203-210.
10. Le JM, Vilcek J. Interleukin-6: a multifunctional cytokine regulating immune reactions and the acute protein response. Lab Invest 1989; 61: 588-602.
11. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp 130. Blood 1995; 86: 1243-1254.
12. Havley RG. Hematopathology of interleukin-6 type cytokines. Stem Cells Dayt 1994; 12: (suppl 1): 155-171.
13. Sprang S, Bazan J. Cytokine structural taxonomy and mechanism of receptor engagement. Curr Opin Struc Biol 1993; 3: 815-821.
14. Robinson RC, Grey LM, Staunton D, Vankelecom H., Vernallis AB, Moreau JF, Stuart DI, Heath JK, Jones EY. The crystal structure and biological function of leukemia inhibitory factor: implication for receptor binding. Cell 1994; 71: 1101-1116.
15. Simpson RJ, Hammacher A, Smith DK, Matthews JM, Ward LD. Interleukin-6: structure, function, relationships. Protein Sci 1997; 6: 929-955.
16. Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 1997; 40: 1096-1105.
17. Waring PM, Carroll GJ, Kandiah DA, Buirski G, Metcalf D. Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflamatory arthritides. Arthritis Rheum 1993; 36: 911-915.
18. Lotz M, Moats T, Villiger PM. Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis. J Clin Invest 1992; 90: 888-896.
19. Robak E, Sysa-Jedrzejowska A, Stepień H, Robak T. Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus. Eur Cytokine Netw 1997; 8: 281-286.
20. Yasukawa K, Futatsugi K, Saito T, Yawata H, Narazaki H, Suzuki H, Taga T, Kishimoto T. Association of recombinant soluble IL-6 signal transducer, gp 130, with a complex of IL-6 and soluble IL-6 receptor and establishment of an ELISA for soluble gp 130. Immunol Lett 1992; 31: 123-130.
21. Peters M, Hermann Meyer K, Rose-John S. The function of the soluble IL-6 receptor in vivo. Immunol Lett 1996; 54: 177-184.
22. Ivashkiv B. Cytokine expression and cell activation in inflammatory arthritis. Adv Immunol 1996; 63: 337-376.
23. Heaney ML, Galde DW. Soluble cytokine receptors. Blood 1996; 87: 847-857.
24. Ropes MW, Bennett GA, Cobb S, Jacox R, Jessat RA. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958; 9: 175-176.
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Measger TAJ, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Scharp JT, Wider RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
26. Ritchie DM, Boyle JA, Mc Innes JM, Jasani MK, Dalakos TG, Grieveson P, Buchanan WW. Clinical studies with an articular index for the assessments of joint tenderness in patients with rheumatoid arthritis. J Med 1968; 147: 393-406.
27. Mallya RK, Mace BE. The assessment of disease activity in rheumatoid arthritis using a multivariate analysis. Rheumatol Rehabil 1981; 20: 14-17.
28. Robak E, Sysa-Jedrzejowska A, Robak T, Stepień H, Woźniacka A, Waszczykowska E. Tumour necrosis factor α (TNF-α), interleukin-6 (IL-6) and their soluble receptors (sTNF-α R p55 and sIL-6R) serum levels in systemic lupus erythematodes. Mediat Inflamm 1996; 5: 435-441.
29. Hui W, Bell M, Carroll G. Detection of oncostatin M in synovial fluid from patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56: 184-187.
30. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, Yamaguchi A, Kishimoto T, Suda T, Kashiwazaki S. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996; 11: 88-95.
31. Desgeorges A, Gabay C, Silacci P, Novick D, Roux-Lombard P, Grau G, Dayer JM, Vischer T, Guerne PA. Concentrations and origins of soluble interleukin-6 receptor-α in serum and synovial fluid. J Rheumatol 1987; 24: 1510-1516.
32. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin-6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993; 52: 232-234.
33. Van Leeuwen MA, Westra J, Limburg PC, van Riel PL, van Rijswijk MH. Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical year prospective study. Ann Rheum Dis 1995; 54: 674-677.
34. Brozik KM, Rosztoczy I, Meretey K, Balint G, Gaal M, Balogh Z, Bart M, Mituszova M, Velics V, Falus A. Interleukin-6 levels in synovial fluids of patients with different arthritides: correlation local IgM rheumatoid factor and systemic acute phase protein production. J Rheumatol 1992; 19: 63-68.
35. Wendling D, Racadot E, Wijdeness J. Treatment of severe rheumatoid arthritis by antiinterleukin-6 monoclonal antibody. J Rheumatol 1993; 20: 259-262.
36. Lorgeot V, Pralran V, Turlure P, Denizot Y. Concentration of serum leukemia inhibitory factor (LIF) in patients with hematologic malignancies (letter). Leukemia 1997; 11: 311-312.
37. Waring P, Wycherley K, Cary D, Nicola N, Metcalf D. Leukemia inhibitory factor levels are elevated in septic shock and various inflammatory body fluids. J Clin Invest 1992; 90; 2031-2037.
38. Fixe P, Lorgeot V, Le Meur YL, Coupey L, Heymann D, Godard A, Praloran V. Development of enzymo-immunoassays (EIA) for macrophage colony-stimulating factor (M-CSF) and leukemia inhibitory factor (LIF) by using the same capture and signal generating polyclonal antibody. Cytokine 1996; 8: 586-591.
39. Gabay C, Singwe M, Genin B, Meyer U, Mentha G, LeCoultre C, Vischer T, Guerne PA. Circulating level of IL-11 and leukemia inhibitory factor (LIF) do not significantly participate in the production of acute phase proteins by the liver. Clin Exp Immunol 1996; 105: 260-265.
40. Espat NJ, Auffenberg T, Rosenberg JJ, Rogy M, Martin D, Fang CH, Hasselgren PO, Copeland EM, Moldawer LL. Ciliary neurotrophic factor is catobolic and shares with IL-6 capacity to induce an acute phase response. Am J Physiol 1996; 271: 185-190.
41. Mackiewicz A, Schooltink H, Heinrich PC, RoseJohn S. Complex of soluble human IL-6 receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 1992; 149: 2021-2027.
42. Gaillard JP, Bataille R, Brailly H, Zuber C, Yasukawa K, Attal M, Maruo N, Taga T, Kishimoto T, Klein B. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammapathy. Eur J Immunol 1993; 23: 820-824.
43. Mihara M, Moria Y, Kishimoto T, Ohsugi Y. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol 1995; 34: 321-325.
44. De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A. Serum soluble interleukin-6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994; 93: 2114-2119.
45. Honda M, Yamamoto S, Cheng M, Yasukawa K, Suzuki H, Saito T, Osugi Y, Tokunaga T, Kishimoto T. Human soluble IL-6 receptor; its detection and enhanced relase by HIV infection. J Immunol 1992; 148: 2170-2180.
46. Smith SR, Morgan L. Soluble IL-6R in plasma cell dyscrasias. Leuk Lymph 1997; 26: 489-495.